Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Axel A. Fauser"'
Autor:
Marc Boogaerts, A. van Biezen, M. Egeler, T. de Witte, Jean-Yves Cahn, Dietger Niederwieser, Axel A. Fauser, Jürgen Finke, H Biersack, Haifa Kathrin Al-Ali, Renate Arnold, Ronald Brand
Publikováno v:
Leukemia, 21, 9, pp. 1945-51
Leukemia, 21, 1945-51
Leukemia, 21, 1945-51
Contains fulltext : 53547.pdf (Publisher’s version ) (Closed access) Hematopoietic cell transplantation (HCT) is an effective treatment for myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML). In this study, outcome of 593 patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9228dfa94e241db13c90782b57076faa
https://hdl.handle.net/2066/53547
https://hdl.handle.net/2066/53547
Autor:
D. W. Beelen, A.R. Zander, Michael G. Kiehl, N Kröger, Tatjana Zabelina, Axel A. Fauser, Rainer Schwerdtfeger, Christian Thiede, Thomas K. Held, Johannes Schetelig, Volker Runde, Wolfgang Siegert, Martin Bornhäuser, G. Ehninger
Publikováno v:
Bone marrow transplantation. 33(5)
It is unknown whether the addition of antithymocyte globulin (ATG) to reduced-intensity conditioning with busulfan (BU) and fludarabine (FLU) is beneficial in HLA-identical sibling transplantation. Therefore, we analyzed retrospectively data on 83 pa
Autor:
Tatjana Zabelina, D. W. Beelen, Rudolf Trenschel, Herrad Baurmann, Nicolaus Kröger, Rainer Schwerdtfeger, Axel R. Zander, Ulrich W. Schaefer, M. Bornhäuser, Jürgen Finke, Hellmut Ottinger, Michael Schleuning, Kolb Hj, G. Ehninger, Berger J, Axel A. Fauser, Michael G. Kiehl, Hartmut Bertz
Publikováno v:
Bone marrow transplantation. 32(4)
Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplant-related mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 33
Publikováno v:
Transplantation. 72(8)
Background Severe acute graft-versus-host disease (aGVHD) of the gut is a serious and frequent posttransplantation event associated with a high mortality rate. We report on our experience with factor XIII replacement in patients with severe aGVHD of
Publikováno v:
Bone marrow transplantation. 25
Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. S
Publikováno v:
Bone marrow transplantation. 25
GVHD continues to be a major complication after allogeneic hematopoietic stem cell transplantation even when the recipient is given immunosuppression for the prophylaxis of this severe disease. There have been many advances in the prevention and trea
Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
Autor:
Nadezda Basara, M Rudolphi, E Römer, Axel A. Fauser, WI Blau, S Günzelmann, H Sanchez, D Kirsten, M Bischoff
Publikováno v:
Bone marrow transplantation. 22(1)
The efficacy and safety of mycophenolate mofetil (MMF) in combination with CsA and prednisolone for the treatment of acute and chronic GVHD (aGVHD and cGVHD, respectively) after BMT and PBSCT from HLA-mismatched and -matched donors was evaluated in a